PharmGen Science Inc Cash Flow Quality Index
PharmGen Science Inc cash flow quality index. PharmGen Science Inc (004720) has a Cash Flow Quality Index of 0.92x as of December 2024. Operating cash flow of ₩3.40 Billion is below net income of ₩3.71 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore how well can PharmGen Science Inc service its debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of PharmGen Science Inc (2015–2024)
Cash flow quality index of PharmGen Science Inc from 2015 to 2024. Historical Cash Flow Quality Index for PharmGen Science Inc across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. See PharmGen Science Inc (004720) net asset quality to measure how much of total assets are equity-financed.
PharmGen Science Inc Cash Flow Quality Index by Year (2015–2024)
PharmGen Science Inc cash flow quality index by year from 2015 to 2024. Year-by-year earnings quality comparison for PharmGen Science Inc. For the full cash flow conversion analysis, see PharmGen Science Inc (004720) cash conversion ratio.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.85x | ₩2.38 Billion | ₩2.79 Billion | ▼ -4.4% |
| 2023 | 0.89x | ₩5.44 Billion | ₩6.09 Billion | ▲ +4965.7% |
| 2022 | -0.02x | ₩-1.29 Billion | ₩70.06 Billion | ▼ -107.7% |
| 2021 | 0.24x | ₩7.78 Billion | ₩32.47 Billion | ▼ -17.4% |
| 2020 | 0.29x | ₩2.68 Billion | ₩9.22 Billion | ▼ -96.5% |
| 2019 | 8.36x | ₩2.52 Billion | ₩301.98 Million | ▲ +785.7% |
| 2018 | 0.94x | ₩4.22 Billion | ₩4.47 Billion | ▲ +121.8% |
| 2017 | 0.43x | ₩1.84 Billion | ₩4.32 Billion | ▼ -81.1% |
| 2016 | 2.25x | ₩7.75 Billion | ₩3.45 Billion | ▲ +28.2% |
| 2015 | 1.75x | ₩3.62 Billion | ₩2.07 Billion | — |